Fibrinolysis and atherosclerosis: An update

Fibrinolysis and Proteolysis

Volumn 8, Issue SUPPL. 1, 1994, Pages 253-262

  Hamsten, A ^a   Eriksson, P ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROSCLEROSIS; CONFERENCE PAPER; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL;

EID: 0028074852     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/0268-9499(94)90723-4     Document Type: Article

References (125)

1. Impaired fibrinolysis and risk of thromboembolism
2. Fibrinolytic activity and coronary-artery disease
3. Blood coagulation and fibrinolysis in man after myocardial infarction compared with a representative population sample
4. Fibrinolytic capacity of arm and leg veins after femoral shaft fracture and acute myocardial infarction
5. Disordered ‘fibrinolytic potential’ in coronary heart disease
6. Fibrinolytic Activity in Men with Acute Myocardial Infarction before 60 Years of Age
7. Haemostatic function and cardiovascular death: early results of a prospective study
8. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study
9. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study
10. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
11. Haemostatic function in myocardial infarction
12. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction
13. On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial reinfarction
14. A selective depression of tissue plasminogen activator (t-PA) activity in euglobulins characterises a risk group among survivors of acute myocardial infarction
15. A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction
16. Increased fibrin turnover and high PAI-I activity as predictors of ischemic events in atherosclerotic patients. A case-control study
17. The hemostatic system and coronary heart disease
18. Elevated levels of the rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction
19. Plasminogen activator inhibitor - a risk factor for myocardial infarction in diabetic subjects
20. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease
21. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations
22. Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries
23. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction
24. The association of hypotestosteronemia with coronary artery disease in men
25. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease
26. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up
27. Endogenous tissue-type plasminogen activator and risk of myocardial infarction
28. Plasma triglyceride as a risk factor for coronary heart disease: the epidemiological evidence and beyond
29. The acute effect of smoking on fibrinolysis: increase in the activity level of circulating extrinsic (tissue-type) plasminogen activator
30. Relationship between smoking and fibrinolytic system with special reference to tPA and PA inhibitor
31. Effect of chronic smoking on fibrinolysis
32. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease
33. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors
34. Hypofibrinolysis in patients with hypertension and elevated cholesterol
35. The effect of body build, diet and endocrine factors on the extrinsic fibrinolytic system in healthy young women
36. Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a North Swedish population
37. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1
38. Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women
39. Relationships between plasma insulin, triglyceride, body mass index, and plasminogen activator inhibitor 1
40. Plasminogen activator inhibitor activity in various types of endogenous hypertriglyceridemia
41. Relationship between plasma plasminogen activator inhibitor- I activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normoand hypertriglyceridemic men
42. Effect of treatment of hyperlipidaemia on haemostatic variables
43. Hypertriglyceridaemia and hypercoagulability
44. Increased fibrinolytic potential after diet intervention in healthy coronary high-risk individuals
45. Effects of gemfibrozil on lipids and haemostasis after myocardial infarction
46. Dietary regulation of fibrinolytic factors
47. Reduction of elevated plasminogen activator inhibitor levels during modest weight loss
48. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen
49. Coronaryheart disease risk and impaired glucose tolerance. The Whitehall Study
50. Coronary heart disease and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations
51. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population
52. Plasma insulin as coronary heart disease risk factor: Relationship to other risk factors and predictive value during 91-year follow up of the Helsinki policeman study population
53. Hyperinsulinemia is characterized by jointly disturbed plasma VLDL, LDL and HDL levels. A population-based study
54. Incidence of NIDDM and impaired glucose tolerance in hypertensioe subjects. The San Antonio Heart Study
55. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis
56. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris
57. Impact of smoking, physical training and weight reduction on FVII, PAI-I and haemostatic markers in sedentary men
58. Impact of weight loss on plasminogen activator inhibitor (PAI-1 ), factor VII, and other hemostatic factors in moderately overweight adults
59. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non diabetic obese subjects
60. Sensitive and specific two site immunoradiometric assays for human insulin, proinsulin, 65–66 split and 32–33 split proinsulins
61. Insulin deficiency in non insulin dependent diabetes
62. The relationships of concentrations of insulin, intact proinsulin and 32–33 split proinsulin with cardiovasculr risk factors in type 2 (non insulin dependent) diabetic subjects
63. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control
64. Short term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man
65. The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man
66. Effects of metformin and metoprolol CR on hormones and fibrinolytic variables during a hyperinsulinaemic, euglycaemic clamp in man
67. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance
68. Weight in infancy and death from ischaemic heart disease
69. Fetal and placental size and risk of hypertension in adult life
70. Fetal and infant growth and impaired glucose tolerance at age 64
71. Type 2 (non insulin dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth
72. Relationship between serum sex hormones and glucose, insulin and lipid abnormalities in men with myocardial infarction.
73. Relationship between sex hormones and the glucose-insulin-lipid defect in men with obesity
74. Plasminogen activator inhibitor in plasma is related to testosterone in men
75. Relation of hemostatic risk factors to other risk factors for coronary heart disease and to sex hormones in men
76. Evidence for hyperoestrogenaemia as a risk factor for myocardial infarction in men
77. Raised plasma oestriol and oestrone levels in young survivors of myocardial infarction
78. Serum estrogen levels in men with acute myocardial infarction
79. Association of hyperestrogenemia and coronary heart disease in men in the Framingham cohort
80. Sex hormones, insulin, lipid, and prevalent ischemic heart disease
81. Plasminogen activator inhibitor-1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism
82. Induction of endothelial cell expression of the plasminogen activator inhibitor type 1 gene by thrombosis in vivo
83. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-I gene
84. Plasminogen Activator Inhibitor-1 Gene-deficient Mice. II. Effects on Hemostasis, Thrombosis, and Thrombolysis
85. Physiological Consequences of loss of plasminogen activator gene function in mice
86. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries
87. Localization and production of plasminogen activator inhibitor-1 inhuman healthy and atherosclerotic arteries
88. Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen activator inhibitor type I in cultured human vascular smooth muscle cells
89. Stimulation of PAII expression in endothelial cells by cultured vascular smooth muscle cells
90. The status of PAI-I as a risk factor for arterial and thrombotic disease: a review
91. Posttranscriptional regulation of expression of plasminogen activator inhibitor type I mRNA by insulin and insulin-like growth factor 1
92. Secretion of plasminogen activator inhibitor- I from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein
93. Hypertriglyceridemia and regulation of fibrinolytic activity
94. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor- I synthesis by endothelial cells
95. Phosphatidylinositol turnover during stimulation of plasminogen activator inhibitor-1 secretion induced by oxidized low density lipoproteins in human endothelial cells
96. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. An LDL receptor-independent phenomenon
97. Low-density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins
98. The LDL-receptor-related protein, LRP is an apolipoprotein Ebinding protein
99. 2-macroglobulin receptor
100. 2-macroglobulin receptor is a hepatic receptor for tissue-type plasminogen activator (t-PA)
101. 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes
102. Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells
103. Lipoprotein (a), fibrin binding and plasminogen activation
104. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin
105. A potential basis for the thrombotic risks associated with lipoprotein(a)
106. Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis
107. Further characterization of the cellular plasminogen binding site: evidence that plasminogen and lipoprotein a compete for the same site
108. Lipoprotein (a) and plasminogen are immunochemically related
109. Lipoprotein(a) inhibits streptokinase-mediated activation of human plasminogen
110. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis
111. Insulin stimulates the synthesis of plasminogen activator inhibitor I by hepatocellular cell line Hep G2
112. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes
113. Augmentation of synthesis of plasminogen activator inhibitor type-I by insulin and insulinlike growth factor type-1: implications for vascular disease by hyperinsulinemic states
114. Stimulation by proinsulin of expression of plasminogen activator inhibitor type-I in endothelial cells
115. Augmentation of the synthesis of plasminogen activator inhibitor type-I by precursors of insulin. A potential risk factor for vascular disease
116. Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin
117. Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose
118. Augmentation of synthesis of plasminogen activator inhibitor type-I in arterial endothelial cells by glucose and its implications for local fibrinolysis
119. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity
120. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-I in HepG2 cells
121. Polymorphisms of the plasminogen activator inhibitor-1 gene in type 1 and type 2 diabetes, and in patients with diabetic retinopathy
122. Lipoprotein (a). A unique risk factor for atherothrombotic disease
123. Regulation of PAI-1 gene expression
124. Plasminogen activator inhibitor 1 and atherothrombosis
125. The relationship of lipoprotein (a) to hemostasis